quinoxalines has been researched along with apraclonidine in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 23 (60.53) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 2 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okuma, Y; Reisine, T | 1 |
| Berridge, TL; Doxey, JC; Roach, AG; Smith, CF | 1 |
| Benishin, C; Fredholm, BB; Hu, PS | 1 |
| del Arco, C; del Olmo, E; Díaz, A; González, AM; Pascual, J; Pazos, A | 1 |
| Chien, DS; Gluchowski, C; Homsy, JJ; Tang-Liu, DD | 1 |
| García-Sáinz, JA; Martínez, OM | 1 |
| Jurcovicová, J; Krulich, L; Le, T | 1 |
| Bylund, DB; Ray-Prenger, C; Turner, JT | 1 |
| Brasier, RS; Gantzos, RD; Neubig, RR | 1 |
| Debink, N; Gabelt, BT; Hubbard, WC; Kaufman, PL; Peterson, CM; Robinson, JC; Wadhwa, A | 1 |
| Serle, JB | 1 |
| Garst, ME; Macdonald, TL; Munk, SA; Thompson, CD; Wiese, A | 1 |
| Garrison, PM; Stewart, WC | 1 |
| Crichton, AC | 1 |
| Gramer, E | 1 |
| Brubaker, RF; Maus, TL; Nau, CB; Schadlu, R | 1 |
| Gordon, RN; Greenfield, DS; Lama, P; Liebmann, JM; Ritch, R | 1 |
| Hoyng, PF; Rasker, MT | 1 |
| Boles Carenini, B; Brogliatti, B; Lo Presti, L; Morgese, A; Ravot, M | 1 |
| Gebhardt, DO | 1 |
| Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR | 1 |
| Burnstein, Y; Robin, AL | 1 |
| Brubaker, RF; Maus, TL; Nau, C | 1 |
| Kaufman, PF | 1 |
| Cha, SC; Glover, BK; Kim, C; Kim, YY; Nguyen, KD; Shin, DH | 1 |
| Barnes, SD; Campagna, JA; Dirks, MS; Doe, EA | 1 |
| Apătăchioae, I; Chiseliţă, D | 1 |
| Connor, TB; Dev, S; Han, DP; Mieler, WF; Mittra, RA; Pollack, JS; Pulido, JS | 1 |
| Gross, RL; Orengo-Nania, S; Williams, GC | 1 |
| Ang, RT; Chen, TC; Fan, JT; Grosskreutz, CL; Pasquale, LR | 1 |
| Burke, JA; Nieves, AL; Spada, CS; Wheeler, LA; Woodward, DF | 1 |
| Simonsen, U; Wikberg-Matsson, A | 1 |
| Chao, HM; Osborne, NN | 1 |
| Ciancaglini, M; Costagliola, C; D'Oronzo, E; Mastropasqua, L; Parmeggiani, F; Sebastiani, A | 1 |
| Chen, TC | 1 |
| Bailly, M; Cosgrave, E; Dahlmann-Noor, AH; Lowe, S; Vivian, AJ | 1 |
| Besada, E; Hardigan, P; Najman, P; Reed, K; Shechtman, D | 1 |
| Dot, C; El Chehab, H; Giraud, JM; Le Corre, A; Ract-Madoux, G; Swalduz, B | 1 |
6 review(s) available for quinoxalines and apraclonidine
| Article | Year |
|---|---|
Pharmacological advances in the treatment of glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Ethacrynic Acid; Glaucoma; Humans; Latanoprost; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1994 |
Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events.
Topics: Adrenergic beta-Antagonists; Brimonidine Tartrate; Cardiovascular System; Central Nervous System; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Neurosecretory Systems; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Respiratory System; Sulfonamides; Thiophenes | 1998 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Therapy, Combination; Female; Glaucoma; Humans; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1998 |
Selectivity of site of action and systemic effects of topical alpha agonists.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ophthalmic Solutions; Optic Nerve; Quinoxalines; Treatment Outcome | 1998 |
Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aqueous Humor; Brimonidine Tartrate; Clonidine; Drug Synergism; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 1999 |
[Alpha-2 adrenergic agonists in the treatment of glaucoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 1999 |
13 trial(s) available for quinoxalines and apraclonidine
| Article | Year |
|---|---|
Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Topics: Adrenergic alpha-Agonists; Adult; Aqueous Humor; Brimonidine Tartrate; Clonidine; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Tonometry, Ocular | 1998 |
Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Cross Reactions; Drug Hypersensitivity; Eye Diseases; Follow-Up Studies; Glaucoma; Humans; Middle Aged; Quinoxalines; Time Factors | 1998 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Chronic Disease; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Observer Variation; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy; Treatment Outcome | 1999 |
Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Clonidine; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fluorophotometry; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 1999 |
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Chronic Disease; Clonidine; Drug Hypersensitivity; Female; Glaucoma, Angle-Closure; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines | 1999 |
Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy | 1999 |
The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade.
Topics: Administration, Topical; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Clonidine; Fluorocarbons; Humans; Intraocular Pressure; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Sulfur Hexafluoride; Thiophenes; Timolol; Vitrectomy | 2000 |
Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Iris; Laser Therapy; Male; Ocular Hypertension; Ophthalmic Solutions; Postoperative Complications; Quinoxalines; Safety; Trabeculectomy | 2001 |
Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Visual Fields | 2002 |
Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Heart Rate; Humans; Intraocular Pressure; Iridectomy; Laser Therapy; Lens Capsule, Crystalline; Male; Ocular Hypertension; Postoperative Complications; Quinoxalines; Trabeculectomy; Treatment Outcome; Visual Acuity | 2005 |
Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.
Topics: Adrenergic alpha-Agonists; Adult; Blood Loss, Surgical; Brimonidine Tartrate; Clonidine; Combined Modality Therapy; Conjunctiva; Humans; Middle Aged; Pilot Projects; Prospective Studies; Quinoxalines; Strabismus; Vasoconstriction; Vasoconstrictor Agents | 2009 |
Pupillometry study of brimonidine tartrate 0.2% and apraclonidine 0.5%.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Humans; Male; Miotics; Photometry; Pupil; Quinoxalines; Young Adult | 2011 |
[Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
Topics: Acetazolamide; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Brimonidine Tartrate; Chemoprevention; Clonidine; Drug Combinations; Female; Humans; Hypotonic Solutions; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Treatment Outcome | 2012 |
19 other study(ies) available for quinoxalines and apraclonidine
| Article | Year |
|---|---|
Immunoprecipitation of alpha 2a-adrenergic receptor-GTP-binding protein complexes using GTP-binding protein selective antisera. Changes in receptor/GTP-binding protein interaction following agonist binding.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Line; Clonidine; Electrophoresis, Polyacrylamide Gel; GTP-Binding Proteins; Immune Sera; Iodine Radioisotopes; Precipitin Tests; Quinoxalines; Receptors, Adrenergic, alpha; Swine; Yohimbine | 1992 |
Selectivity profile of the alpha 2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Benzofurans; Blood Glucose; Brimonidine Tartrate; Clonidine; Decerebrate State; Dioxanes; Dose-Response Relationship, Drug; Epinephrine; Idazoxan; Imidazoles; Insulin; Male; Muscles; Prazosin; Quinoxalines; Rats; Rats, Inbred Strains; Vas Deferens | 1992 |
Comparison of the effects of four dendrotoxin peptides, 4-aminopyridine and tetraethylammonium on the electrically evoked [3H]noradrenaline release from rat hippocampus.
Topics: 4-Aminopyridine; Adrenergic alpha-Agonists; Animals; Binding, Competitive; Brimonidine Tartrate; Clonidine; Elapid Venoms; Electric Stimulation; Hippocampus; Male; Norepinephrine; Peptide Fragments; Peptides; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Tetraethylammonium; Tetraethylammonium Compounds; Tritium | 1991 |
Regionally specific age-dependent decline in alpha 2-adrenoceptors: an autoradiographic study in human brain.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Aging; Autoradiography; Brain; Brimonidine Tartrate; Clonidine; Humans; Middle Aged; Organ Specificity; Postmortem Changes; Quinoxalines; Receptors, Adrenergic, alpha; Tritium | 1991 |
Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes.
Topics: Absorption; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Clonidine; Conjunctiva; Cornea; Eye; Female; Perfusion; Permeability; Quinoxalines; Rabbits; Sclera; Solubility; Tissue Distribution | 1990 |
Functional alpha 2-adrenoceptors in rat adipocytes: inhibition of cyclic AMP accumulation.
Topics: Adenylate Cyclase Toxin; Adipose Tissue; Animals; Brimonidine Tartrate; Clonidine; Colforsin; Cricetinae; Cyclic AMP; Male; Pertussis Toxin; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Virulence Factors, Bordetella | 1989 |
The paradox of alpha 2 adrenergic regulation of prolactin (PRL) secretion. I. The PRL-releasing action of the alpha 2 receptor agonists.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Clonidine; Growth Hormone; Injections, Intravenous; Male; Nervous System; Prolactin; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha | 1989 |
Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
Topics: Adenocarcinoma; Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Brimonidine Tartrate; Cell Line; Clonidine; Colforsin; Colonic Neoplasms; Dose-Response Relationship, Drug; Guanosine Triphosphate; Humans; Kinetics; Magnesium; Quinoxalines; Radioligand Assay; Receptors, Adrenergic, alpha; Vasoactive Intestinal Peptide; Yohimbine | 1985 |
Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
Topics: Adenosine Diphosphate Ribose; Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Platelets; Brimonidine Tartrate; Clonidine; GTP-Binding Proteins; Guanylyl Imidodiphosphate; Humans; In Vitro Techniques; NAD; Quinoxalines; Receptors, Adrenergic, alpha; Yohimbine | 1985 |
Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Blood Pressure; Body Weight; Brimonidine Tartrate; Clonidine; Dose-Response Relationship, Drug; Female; Heart Rate; Intraocular Pressure; Macaca fascicularis; Macaca mulatta; Male; Pupil; Quinoxalines; Refraction, Ocular; Sympathectomy | 1994 |
Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation.
Topics: Adrenergic alpha-Agonists; Allergens; Amodiaquine; Brimonidine Tartrate; Clonidine; Epinephrine; Glutathione; Horseradish Peroxidase; Magnetic Resonance Spectroscopy; Oxidation-Reduction; Quinoxalines | 1997 |
Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Quinoxalines | 1998 |
[New drugs in glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 1998 |
Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Chamber; Brimonidine Tartrate; Ciliary Body; Clonidine; Deoxyepinephrine; Female; Follow-Up Studies; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Mydriatics; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Reference Values; Ultrasonography | 1998 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Approval; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Netherlands; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1999 |
Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Clonidine; Conjunctivitis; Cross Reactions; Dermatitis, Allergic Contact; Drug Hypersensitivity; Female; Glaucoma; Humans; Hyperemia; Incidence; Male; Middle Aged; Quinoxalines; Retrospective Studies; Risk Factors | 2000 |
Differential effects of alpha-adrenoceptor agonists on human retinal microvessel diameter.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Cheek; Clonidine; Cricetinae; Humans; Mesocricetus; Muscle, Smooth, Vascular; Quinoxalines; Retina; Retinal Vessels; Vasoconstriction | 2001 |
Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Ciliary Arteries; Clonidine; Dose-Response Relationship, Drug; Isometric Contraction; Muscle, Smooth, Vascular; Oxymetazoline; Quinoxalines; Receptors, Adrenergic, alpha-2; Swine; Vasoconstriction | 2001 |
Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Bridged Bicyclo Compounds; Brimonidine Tartrate; Calbindin 2; Cell Death; Choline O-Acetyltransferase; Clonidine; Electroretinography; Heptanes; Imidazoline Receptors; Immunohistochemistry; Membrane Potentials; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2; Receptors, Drug; Reperfusion Injury; Retina; Retinal Ganglion Cells; S100 Calcium Binding Protein G; Yohimbine | 2001 |